Investigating the role of tumour cell derived iNOS on tumour growth and vasculature in vivo using a tetracycline regulated expression system

International Journal of Cancer

Volumn 138, Issue 11, 2016, Pages 2678-2687

  Papaevangelou, Efthymia ^a   Whitley, Guy S ^a   Johnstone, Alan P ^a   Robinson, Simon P ^b   Howe, Franklyn A ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

inducible expression; MRI; nitric oxide; nitric oxide synthase; tumour vessel maturation

Indexed keywords

CARBOGEN; DOXYCYCLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TETRACYCLINE; VASCULOTROPIN; CONTRAST MEDIUM; FREE RADICAL; NOS2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION SYSTEM; GLIOMA; GLIOMA CELL LINE; HEMODYNAMIC VASCULATURE; HEMODYNAMICS; HISTOPATHOLOGY; HYPOXIA; IN VIVO STUDY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; TUMOR FRACTIONAL BLOOD VOLUME; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; FREE RADICALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; TETRACYCLINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962228101     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29997     Document Type: Article

References (47)

1. Janakiram NB, Rao CV., iNOS-selective inhibitors for cancer prevention: promise and progress. Future Med Chem 2012; 4: 2193-204.
2. D'Amato RJ, Loughnan MS, Flynn E, et al., Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-5.
3. Fukumura D, Kashiwagi S, Jain RK., The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-34.
4. Lechner M, Lirk P, Rieder J., Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol 2005; 15: 277-89.
5. Lala PK, Chakraborty C., Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-56.
6. Ambs S, Merriam WG, Bennett WP, et al., Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998; 58: 334-41.
7. Cobbs CS, Brenman JE, Aldape KD, et al., Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995; 55: 727-30.
8. Eyler CE, Wu Q, Yan K, et al., Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011; 146: 53-66.
9. Cullis ER, Kalber TL, Ashton SE, et al., Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 2006; 71: 76-84.
10. Jenkins DC, Charles IG, Thomsen LL, et al., Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 1995; 92: 4392-6.
11. Coulter JA, Page NL, Worthington J, et al., Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med 2010; 12: 755-65.
12. Xie K, Huang S, Dong Z, et al., Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181: 1333-43.
13. Pipili-Synetos E, Papageorgiou A, Sakkoula E, et al., Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116: 1829-34.
14. Jadeski LC, Lala PK., Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155: 1381-90.
15. Konopka TE, Barker JE, Bamford TL, et al., Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001; 61: 3182-7.
16. Kamba T, McDonald DM., Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-95.
17. Malcolm GP, Jodrell DI, MacLellan A, et al., Effects of nitric oxide manipulation on the disposition of platinum in an experimental glioma model. Neuroreport 1998; 9: 181-5.
18. Gratton JP, Lin MI, Yu J, et al., Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003; 4: 31-9.
19. Ng QS, Goh V, Milner J, et al., Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 2007; 8: 111-18:
20. Ambs S, Merriam WG, Ogunfusika MO, et al., p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4: 1371-6.
21. Yamaguchi S, Bell HS, Shinoda J, et al., Glioma tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal implantation glioma model. Br J Neurosurg 2002; 16: 567-72.
22. Kostourou V, Cartwright JE, Johnstone AP, et al., The role of tumour-derived iNOS in tumour progression and angiogenesis. Br J Cancer 2011; 104: 83-90.
23. Di Rosa M, Radomski M, Carnuccio R, et al., Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 1990; 172: 1246-52.
24. Miranda KM, Espey MG, Wink DA., A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62-71.
25. Bradford MM., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
26. Abramovitch R, Frenkiel D, Neeman M., Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 1998; 39: 813-24.
27. Howe FA, Robinson SP, McIntyre DJ, et al., Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14: 497-506.
28. Robinson SP, Rodrigues LM, Howe FA, et al., Effects of different levels of hypercapnic hyperoxia on tumour R(2)∗ and arterial blood gases. Magn Reson Imaging 2001; 19: 161-6.
29. Tropres I, Grimault S, Vaeth A, et al., Vessel size imaging. Magn Reson Med 2001; 45: 397-408.
30. Schneider CA, Rasband WS, Eliceiri KW., NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-5.
31. Vannini F, Kashfi K, Nath N., The dual role of iNOS in cancer. Redox Biol 2015; 6: 334-43.
32. Borutaite V, Budriunaite A, Brown GC., Reversal of nitric oxide-, peroxynitrite- and S-nitrosothiol-induced inhibition of mitochondrial respiration or complex I activity by light and thiols. Biochimica Et Biophysica Acta 2000; 1459: 405-12.
33. Lee DH, Pfeifer GP., Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis 2007; 22: 63-7.
34. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B., Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48: 565-70.
35. Oronsky BT, Scicinski JJ, Reid T, et al., Beyond antiangiogenesis: vascular modulation as an anticancer therapy-A review. Translat Oncol 2012; 5: 133-40.
36. Gossen M, Bujard H., Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-51.
37. Senner V, Sturm A, Hoess N, Wassmann H, Paulus W., In vivo glioma model enabling regulated gene expression. Acta Neuropathol 2000; 99: 603-8.
38. Swaroop GR, Kelly PA, Bell HS, Shinoda J, Yamaguchi S, Whittle IR., The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br J Neurosurg 2000; 14: 543-8.
39. Jadeski LC, Hum KO, Chakraborty C, et al., Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000; 86: 30-9.
40. Whittle IR, Collins F, Kelly PA, et al., Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow. Acta Neurochirurgica 1996; 138: 870-5.
41. Swaroop GR, Malcolm GP, Kelly PA, et al., Effects of nitric oxide modulation on tumour blood flow and microvascular permeability in C6 glioma. Neuroreport 1998; 9: 2577-81.
42. Howe FA, McPhail LD, Griffiths JR, et al., Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. Int J Radiat Oncol Biol Phys 2008; 71: 1470-6.
43. Abramovitch R, Dafni H, Smouha E, et al., In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 1999; 59: 5012-6.
44. Burrell JS, Walker-Samuel S, Baker LC, et al., Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. Int J Cancer 2012; 131: 1854-62.
45. Burrell JS, Walker-Samuel S, Baker LC, et al., Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging. Magn Reson Med 2011; 66: 227-34.
46. Kashiwagi S, Izumi Y, Gohongi T, et al., NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 2005; 115: 1816-27.
47. Yu J, deMuinck ED, Zhuang Z, et al., Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A 2005; 102: 10999-1004.